{
    "id": "MISSION-500-184-1771352866204",
    "questionType": "clozeDropdown",
    "caseId": "tPAAudit-SafetyStop-01",
    "difficulty": 5,
    "cognitiveLevel": "Analyzing/Evaluating",
    "clientNeeds": [
        {
            "category": "Safe and Effective Care Environment",
            "subcategory": "Safety and Infection Control"
        },
        {
            "category": "Physiological Integrity",
            "subcategory": "Pharmacological and Parenteral Therapies"
        }
    ],
    "tags": [
        "tPA",
        "alteplase",
        "stroke",
        "CVA",
        "contraindication",
        "safety",
        "pharmacology",
        "neurology"
    ],
    "itemStem": "The nurse is preparing to administer alteplase to a 68-year-old client diagnosed with an acute ischemic stroke. The nurse reviews the most recent data in the electronic health record before proceeding. The nurse identifies that the client's [Drop1] is the most critical finding. This finding represents a(n) [Drop2]. Therefore, the nurse's priority action is to [Drop3].",
    "tabs": [
        {
            "title": "Nurses' Notes",
            "content": "A 68-year-old male client brought to the ED by his son. Onset of symptoms (slurred speech, right facial droop, right arm weakness) was witnessed 2 hours ago. Client's primary language is not English; a hospital-approved video remote interpreter is being used for communication. The son reports the client had a 'minor stumble' while gardening about 10 days ago but had no apparent injuries and did not seek medical care. NIHSS score on admission was 14. Alteplase checklist initiated."
        },
        {
            "title": "Vital Signs",
            "content": [
                {
                    "time": "14:00 (Admission)",
                    "BP": "192/110 mmHg",
                    "HR": "95 bpm",
                    "RR": "18/min",
                    "SpO2": "96% on room air",
                    "Temp": "37.1°C (98.8°F)"
                },
                {
                    "time": "14:30",
                    "BP": "184/108 mmHg",
                    "HR": "88 bpm",
                    "RR": "16/min",
                    "SpO2": "97% on room air",
                    "Temp": "37.1°C (98.8°F)"
                }
            ]
        },
        {
            "title": "Laboratory Results",
            "content": [
                {
                    "lab": "Platelet Count",
                    "value": "45,000/mm³",
                    "reference": "150,000-450,000/mm³"
                },
                {
                    "lab": "INR",
                    "value": "1.1",
                    "reference": "0.9-1.2"
                },
                {
                    "lab": "PTT",
                    "value": "29 seconds",
                    "reference": "25-35 seconds"
                },
                {
                    "lab": "Serum Glucose",
                    "value": "142 mg/dL",
                    "reference": "70-110 mg/dL"
                },
                {
                    "lab": "Troponin I",
                    "value": "<0.01 ng/mL",
                    "reference": "<0.04 ng/mL"
                }
            ]
        },
        {
            "title": "Diagnostic Results",
            "content": "<b>Non-Contrast Head CT:</b> No evidence of acute intracranial hemorrhage. Findings are consistent with an evolving ischemic infarct in the left middle cerebral artery (MCA) territory.\n\n<b>ECG:</b> Normal sinus rhythm, rate 89 bpm. No acute ischemic changes."
        },
        {
            "title": "MAR",
            "content": [
                {
                    "medication": "Alteplase (tPA) IV",
                    "dose": "Per stroke protocol",
                    "route": "IV",
                    "frequency": "STAT",
                    "status": "Pending"
                },
                {
                    "medication": "Labetalol 10 mg",
                    "dose": "10 mg",
                    "route": "IV Push",
                    "frequency": "PRN for SBP > 185 mmHg or DBP > 110 mmHg",
                    "status": "Administered at 14:05"
                }
            ]
        }
    ],
    "options": {
        "Drop1": [
            {
                "id": "D1_Opt1",
                "text": "platelet count"
            },
            {
                "id": "D1_Opt2",
                "text": "blood pressure trend"
            },
            {
                "id": "D1_Opt3",
                "text": "non-contrast head CT result"
            },
            {
                "id": "D1_Opt4",
                "text": "report of a 'minor stumble'"
            }
        ],
        "Drop2": [
            {
                "id": "D2_Opt1",
                "text": "relative contraindication requiring physician discussion"
            },
            {
                "id": "D2_Opt2",
                "text": "absolute contraindication to thrombolytic therapy"
            },
            {
                "id": "D2_Opt3",
                "text": "finding that supports proceeding with treatment"
            },
            {
                "id": "D2_Opt4",
                "text": "common hematological response to acute stroke"
            }
        ],
        "Drop3": [
            {
                "id": "D3_Opt1",
                "text": "request a repeat complete blood count (CBC)"
            },
            {
                "id": "D3_Opt2",
                "text": "proceed with administering the alteplase bolus"
            },
            {
                "id": "D3_Opt3",
                "text": "withhold the alteplase and notify the stroke team physician immediately"
            },
            {
                "id": "D3_Opt4",
                "text": "administer a second dose of labetalol per protocol"
            }
        ]
    },
    "correctAnswer": [
        "D1_Opt1",
        "D2_Opt2",
        "D3_Opt3"
    ],
    "answerBreakdown": {
        "Drop1": [
            {
                "optionId": "D1_Opt1",
                "rationale": "Correct. The platelet count of 45,000/mm³ is critically low (thrombocytopenia) and is the most significant finding. It is an absolute contraindication for alteplase due to the extremely high risk of life-threatening hemorrhage."
            },
            {
                "optionId": "D1_Opt2",
                "rationale": "Incorrect. While the blood pressure is elevated, it is trending down after labetalol administration and approaching the acceptable threshold of <185/110 mmHg for tPA. This requires monitoring but is not the most critical finding compared to the severe thrombocytopenia."
            },
            {
                "optionId": "D1_Opt3",
                "rationale": "Incorrect. The non-contrast head CT showing no hemorrhage is a necessary prerequisite *for* administering alteplase. This finding supports, rather than opposes, the treatment plan."
            },
            {
                "optionId": "D1_Opt4",
                "rationale": "Incorrect. While a recent history of trauma can be a contraindication, the report of a 'minor stumble' 10 days ago is less definitive and critical than the objective laboratory finding of severe thrombocytopenia. The low platelet count is the immediate, absolute contraindication."
            }
        ],
        "Drop2": [
            {
                "optionId": "D2_Opt1",
                "rationale": "Incorrect. Thrombocytopenia with a platelet count < 100,000/mm³ is considered an absolute, not relative, contraindication for alteplase administration. The risk of hemorrhage is unacceptably high."
            },
            {
                "optionId": "D2_Opt2",
                "rationale": "Correct. A platelet count of 45,000/mm³ is well below the 100,000/mm³ threshold, making it an absolute contraindication to thrombolytic therapy. Proceeding would place the client at extreme risk for intracranial or systemic bleeding."
            },
            {
                "optionId": "D2_Opt3",
                "rationale": "Incorrect. The critically low platelet count is a major safety concern that halts treatment; it does not support proceeding."
            },
            {
                "optionId": "D2_Opt4",
                "rationale": "Incorrect. Severe thrombocytopenia is not an expected or common response to an acute ischemic stroke. It suggests an underlying hematological issue that must be addressed and contraindicates thrombolysis."
            }
        ],
        "Drop3": [
            {
                "optionId": "D3_Opt1",
                "rationale": "Incorrect. While a repeat lab might be ordered later, the priority is to act on the current, critical result. Delaying the decision to withhold the medication while waiting for a new lab result exposes the client to the risk of inappropriate administration."
            },
            {
                "optionId": "D3_Opt2",
                "rationale": "Incorrect. This action is extremely dangerous and could lead to a fatal hemorrhagic event. It demonstrates a failure to recognize a critical contraindication."
            },
            {
                "optionId": "D3_Opt3",
                "rationale": "Correct. This is the 'SAFETY STOP' action. Recognizing the absolute contraindication, the nurse's primary responsibility is to withhold the medication and immediately communicate this critical finding to the provider to ensure the plan of care is re-evaluated and patient safety is maintained."
            },
            {
                "optionId": "D3_Opt4",
                "rationale": "Incorrect. This action addresses the blood pressure, which is a secondary concern compared to the absolute contraindication of severe thrombocytopenia. The nurse must prioritize the most life-threatening issue."
            }
        ]
    }
}